An updated World Health Organization (WHO) classification of female genital tumours was
published in autumn 2020. We discuss the major new additions to and changes from the …

Vulvar squamous cell carcinoma (VSCC) accounts for> 90% of the malignant tumours of the
vulva. Most VSCC s originate in intraepithelial lesions, named vulvar intraepithelial …

Abstract Background Survival differences across Europe for patients with cancers of breast,
uterus, cervix, ovary, vagina and vulva have been documented by previous EUROCARE …

Objective Using highly sensitive polymerase chain reaction (PCR) techniques, we
reanalysed all cervical carcinomas (CC s) found to be human papillomavirus (HPV) …

Human papillomaviruses (HPV) are the causative agents of virtually all cervical carcinomas.
Nevertheless, a small proportion of cervical cancer are negative for HPV, although the …

Primary vaginal malignancies are rare, comprising only 2% of all female genital tract
malignancies in adults and 4.5% in children. As part of its mission to improve the quality of …

Squamous cell carcinoma of the vagina accounts for less than 2% of all gynecologic
malignancies. Surgery has a role in selected cases only. The standard treatment is …

Introduction Based on their etiological relationship with human papillomavirus (HPV), the
2020 WHO classification has divided vulvar squamous cell carcinomas (VSCC) into two …

Cervical cancer (CC) is the fourth most frequent cancer in women worldwide. HPV infection
is associated with the majority of CC cases, but a small proportion of CCs actually test …

Introduction Human papillomavirus (HPV), p16, and p53 have been investigated as
prognostic markers in various HPV‐related cancers. Within the field of vaginal cancer …